NCT03187262View on ClinicalTrials.gov

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

January 31, 2021

Study Completion Date

December 31, 2021

Conditions

Waldenström Macroglobulinemia

Interventions

DRUG

Daratumumab

Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories

Trial Locations (5)

10065

Memorial Sloan-Kettering Cancer Center, New York

55905

Mayo Clinic, Rochester

98109

University of Washington, Seattle

02214

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Janssen, LP

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03187262 - A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia | Biotech Hunter | Biotech Hunter